CA3112735A1 - 1h-indazole carboxamides as receptor-interacting protein kinase 1 inhibitors (ripk1) - Google Patents
1h-indazole carboxamides as receptor-interacting protein kinase 1 inhibitors (ripk1) Download PDFInfo
- Publication number
- CA3112735A1 CA3112735A1 CA3112735A CA3112735A CA3112735A1 CA 3112735 A1 CA3112735 A1 CA 3112735A1 CA 3112735 A CA3112735 A CA 3112735A CA 3112735 A CA3112735 A CA 3112735A CA 3112735 A1 CA3112735 A1 CA 3112735A1
- Authority
- CA
- Canada
- Prior art keywords
- alkyl
- phenyl
- cycloalkyl
- heterocycle
- deuteroalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862730602P | 2018-09-13 | 2018-09-13 | |
| US62/730,602 | 2018-09-13 | ||
| PCT/US2019/050719 WO2020056072A1 (en) | 2018-09-13 | 2019-09-12 | 1h-indazole carboxamides as receptor-interacting protein kinase 1 inhibitors (ripk1) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3112735A1 true CA3112735A1 (en) | 2020-03-19 |
Family
ID=68073171
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3112735A Pending CA3112735A1 (en) | 2018-09-13 | 2019-09-12 | 1h-indazole carboxamides as receptor-interacting protein kinase 1 inhibitors (ripk1) |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US12172975B2 (enExample) |
| EP (1) | EP3849968B1 (enExample) |
| JP (1) | JP7599411B2 (enExample) |
| KR (1) | KR102906523B1 (enExample) |
| CN (1) | CN112673000B (enExample) |
| AU (1) | AU2019337612A1 (enExample) |
| BR (1) | BR112021004385A2 (enExample) |
| CA (1) | CA3112735A1 (enExample) |
| EA (1) | EA202190718A1 (enExample) |
| ES (1) | ES2936481T3 (enExample) |
| IL (1) | IL281370A (enExample) |
| MX (1) | MX2021002509A (enExample) |
| SG (1) | SG11202102405YA (enExample) |
| WO (1) | WO2020056072A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3704118T3 (da) | 2017-10-30 | 2022-03-14 | Bristol Myers Squibb Co | Aminoimidazopyrazin som kinasehæmmere |
| SG11202007035YA (en) | 2018-01-26 | 2020-08-28 | Bristol Myers Squibb Co | Aminopyrrolotriazines as kinase inhibitors |
| EP3849969B1 (en) | 2018-09-13 | 2023-04-19 | Bristol-Myers Squibb Company | Indazole carboxamides as kinase inhibitors |
| WO2021067654A1 (en) * | 2019-10-03 | 2021-04-08 | Bristol-Myers Squibb Company | Indazole carboxamides as kinase inhibitors |
| KR20230067669A (ko) * | 2020-09-15 | 2023-05-16 | 주식회사 퍼스트바이오테라퓨틱스 | 2-아미노-3-카르보닐 이미다조피리딘 및 피라졸로피리딘 화합물 |
| AR123793A1 (es) | 2020-10-19 | 2023-01-11 | Bristol Myers Squibb Co | Compuestos de triazolopiridinilo como inhibidores de quinasas |
| WO2025106362A1 (en) * | 2023-11-16 | 2025-05-22 | Merck Sharp & Dohme Llc | Ripk1 inhibitors and methods of use |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1648455A4 (en) | 2003-07-23 | 2009-03-04 | Exelixis Inc | MODULATORS OF ALK PROTEIN (ANAPLASTIC LYMPHOMA KINASE) AND METHODS OF USE |
| CA2591817A1 (en) | 2004-12-22 | 2006-06-29 | Memory Pharmaceuticals Corporation | Nicotinic alpha-7 receptor ligands and preparation and uses thereof |
| PL2018380T3 (pl) | 2006-05-19 | 2012-05-31 | Abbvie Bahamas Ltd | Skondensowane azabicykliczne pochodne alkanowe podstawione bicykloheterocyklem o aktywności wobec OUN |
| KR101061599B1 (ko) | 2008-12-05 | 2011-09-02 | 한국과학기술연구원 | 비정상 세포 성장 질환의 치료를 위한 단백질 키나아제 저해제인 신규 인다졸 유도체, 이의 약학적으로 허용가능한염 및 이를 유효성분으로 함유하는 약학적 조성물 |
| US20110237633A1 (en) | 2008-12-11 | 2011-09-29 | Bijoy Panicker | Small molecule modulators of hepatocyte growth factor (scatter factor) activity |
| CA2759083A1 (en) | 2009-04-30 | 2010-11-04 | Novartis Ag | Imidazole derivatives and their use as modulators of cyclin dependent kinases |
| US8455516B2 (en) | 2010-01-15 | 2013-06-04 | Touro University | HIV-1 fusion inhibitors and methods |
| KR20130077390A (ko) * | 2011-12-29 | 2013-07-09 | 제이더블유중외제약 주식회사 | 단백질 키나아제 저해활성을 가지는 6-아미노-3-카복스아미도인다졸 유도체 |
| BR112014018657B1 (pt) | 2012-02-21 | 2022-08-02 | Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A | Compostos de 1h-indazol-3-carboxamida |
| AU2013224302B2 (en) | 2012-02-21 | 2017-03-30 | Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. | 1H-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors |
| US9783573B2 (en) | 2012-09-18 | 2017-10-10 | Bristol-Myers Squibb Company | IAP antagonists |
| JP6215338B2 (ja) | 2012-11-08 | 2017-10-18 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | キナーゼモジュレーターとして有用な二環式ヘテロ環置換ピリジル化合物 |
| CN106535890A (zh) | 2014-03-20 | 2017-03-22 | 萨穆梅德有限公司 | 5‑取代的吲唑‑3‑羧酰胺及其制备和应用 |
| WO2017201585A1 (en) | 2016-05-26 | 2017-11-30 | Genea Ip Holdings Pty Ltd | Modulators of dux4 for regulation of muscle function |
| EP3580220B1 (en) | 2017-02-13 | 2021-11-17 | Bristol-Myers Squibb Company | Aminotriazolopyridines as kinase inhibitors |
| DK3704118T3 (da) | 2017-10-30 | 2022-03-14 | Bristol Myers Squibb Co | Aminoimidazopyrazin som kinasehæmmere |
| SG11202007035YA (en) | 2018-01-26 | 2020-08-28 | Bristol Myers Squibb Co | Aminopyrrolotriazines as kinase inhibitors |
| EP3849969B1 (en) * | 2018-09-13 | 2023-04-19 | Bristol-Myers Squibb Company | Indazole carboxamides as kinase inhibitors |
| WO2021067654A1 (en) | 2019-10-03 | 2021-04-08 | Bristol-Myers Squibb Company | Indazole carboxamides as kinase inhibitors |
-
2019
- 2019-09-12 EP EP19779240.1A patent/EP3849968B1/en active Active
- 2019-09-12 US US17/274,220 patent/US12172975B2/en active Active
- 2019-09-12 SG SG11202102405YA patent/SG11202102405YA/en unknown
- 2019-09-12 CA CA3112735A patent/CA3112735A1/en active Pending
- 2019-09-12 AU AU2019337612A patent/AU2019337612A1/en not_active Abandoned
- 2019-09-12 WO PCT/US2019/050719 patent/WO2020056072A1/en not_active Ceased
- 2019-09-12 EA EA202190718A patent/EA202190718A1/ru unknown
- 2019-09-12 BR BR112021004385-3A patent/BR112021004385A2/pt not_active Application Discontinuation
- 2019-09-12 MX MX2021002509A patent/MX2021002509A/es unknown
- 2019-09-12 ES ES19779240T patent/ES2936481T3/es active Active
- 2019-09-12 JP JP2021513958A patent/JP7599411B2/ja active Active
- 2019-09-12 KR KR1020217010498A patent/KR102906523B1/ko active Active
- 2019-09-12 CN CN201980059445.8A patent/CN112673000B/zh active Active
-
2021
- 2021-03-09 IL IL281370A patent/IL281370A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3849968A1 (en) | 2021-07-21 |
| AU2019337612A1 (en) | 2021-05-13 |
| KR102906523B1 (ko) | 2025-12-30 |
| US12172975B2 (en) | 2024-12-24 |
| MX2021002509A (es) | 2021-04-28 |
| BR112021004385A2 (pt) | 2021-07-20 |
| SG11202102405YA (en) | 2021-04-29 |
| EA202190718A1 (ru) | 2021-07-01 |
| KR20210060517A (ko) | 2021-05-26 |
| CN112673000B (zh) | 2024-10-18 |
| JP2022500418A (ja) | 2022-01-04 |
| CN112673000A (zh) | 2021-04-16 |
| ES2936481T3 (es) | 2023-03-17 |
| WO2020056072A1 (en) | 2020-03-19 |
| IL281370A (en) | 2021-04-29 |
| JP7599411B2 (ja) | 2024-12-13 |
| US20220380335A1 (en) | 2022-12-01 |
| EP3849968B1 (en) | 2022-12-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102549952B1 (ko) | 키나제 억제제로서의 아미노트리아졸로피리딘 | |
| EP3849968B1 (en) | 1h-indazole carboxamides as receptor-interacting protein kinase 1 inhibitors (ripk1) | |
| US11440913B2 (en) | Aminoimidazopyridazines as kinase inhibitors | |
| US12084426B2 (en) | Indazole carboxamides as kinase inhibitors | |
| CA3088548A1 (en) | Aminopyrrolotriazines as kinase inhibitors | |
| EP4037772B1 (en) | Indazole carboxamides as kinase inhibitors | |
| EA042124B1 (ru) | Аминоимидазопиридазины в качестве ингибиторов киназ |